The main focus of NextGen Oncology Group is a further development of assays for precision oncology therapy. Since tumors are as individual as a fingerprint, cancer treatment can only be successful if it takes this individuality into account.
Standard treatment in patients with tumor diseases
Ignoring profound differences between cancers of individual patients all are treated the same.
Some patients benefit, some patients do not benefit, and other patients experience adverse drug effects, only.
Advantage of precision oncology
Biomarker-driven personalized treatment
Each patient benefits from receiving a treatment that matches his/her cancer type and biomarker profile.
Using highly innovative assays, we determine a patient’s genetic fingerprint.
The assay spectrum includes chip-based transcriptome analyses, enhanced by immunohistochemistry and quantitative PCR (PANTHER Assay), various cancer gene mutation panels designed for tissue samples and liquid biopsy (cfDNA), and other tests (circulating tumor cell quantification, chemosensitivity testing) which are fundamental for a personalized cancer treatment.
By analyzing all human protein-coding genes for mutations (exome analysis) a tumor’s individual mutation profile can be determined. Such profiles can be used for the development of personalized cancer vaccines on the basis of mutated neoantigen peptides.
Individual cancer genetics data have got important impact for current personalized treatment and will significantly change the therapy of tumor diseases in the years to come.